Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial
Authors:
- 1 February 2014
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 13 (2) , 150-158
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Sporadic human prion diseases: molecular insights and diagnosisThe Lancet Neurology, 2012
- PrionsCold Spring Harbor Perspectives in Biology, 2011
- A systematic review of prion therapeutics in experimental modelsBrain, 2006
- Sporadic Creutzfeldt-Jakob Disease: The Extent of Microglia Activation Is Dependent on the Biochemical Type of PrPScJournal of Neuropathology & Experimental Neurology, 2005
- Compassionate use of quinacrine in Creutzfeldt–Jakob disease fails to show significant effectsNeurology, 2004
- Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathiesBrain, 2004
- Efficacy of flupirtine on cognitive function in patients with CJDNeurology, 2004
- Molecular classification of sporadic Creutzfeldt–Jakob diseaseBrain, 2003
- Therapeutic approaches to prion diseasesClinics In Laboratory Medicine, 2003
- Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjectsAnnals of Neurology, 1999